On October 24, 2025, Alphamab Oncology announced the grant of 1,990,176 award shares to three eligible participants under its Restricted Share Award Scheme. According to the announcement, the participants comprise two executive directors, including Chairman of the Board Dr. Xu Ting, and one employee of the group. The shares are subject to performance targets and vesting schedules set up to incentivize and retain key contributors.

A detailed breakdown reveals that 970,088 award shares are granted to each of the two executive directors and 50,000 award shares to an employee. A 10-year validity period from the date of grant applies, and a performance review mechanism determines vesting, with specified clawback terms in place. The company reports that 362,683 shares come from existing trust-held shares, while 1,627,493 will be satisfied by issuing new shares or transferring treasury shares.

After this grant, Alphamab Oncology indicates that 94,366,279 shares remain available for future awards. The company emphasizes that recognizing contributions and encouraging ongoing commitment to the group's long-term development underpin the grant of these award shares.